Literature DB >> 35966377

Acute Colonic Pseudo-Obstruction.

Thomas Arthur1,2,3, Adele Burgess1,4.   

Abstract

Acute colonic pseudo-obstruction (ACPO) is a functional disorder of the large intestine distinguished by colonic dysmotility resulting in colonic distension in the absence of mechanical obstruction. The underlying pathophysiology of ACPO remains unclear despite technological advances in understanding the physiology of colonic motility, such as spatio-temporal mapping and high-resolution manometry. In many ways, the management of ACPO has remained relatively unchanged for 40 years. Patients with perforation or suspected ischemia undergo operative intervention, while patients without undergo initial conservative management with bowel rest, correction of electrolyte disturbances, and mobilization. Patients who fail conservative management or have prominent cecal dilatation undergo decompression with either neostigmine or colonoscopy. A subset of patients with ACPO will have recurrent symptoms despite endoscopic and medical management. For these patients who are difficult to manage, an underlying colonic functional disorder, such as slow-transit dysmotility or chronic intestinal pseudo-obstruction may be considered. The following review of ACPO aims to provide a concise update of the causes, diagnosis, and management of this emergency surgical condition. Thieme. All rights reserved.

Entities:  

Keywords:  Ogilvie's syndrome; acute colonic pseudo-obstruction; colonic ileus; large bowel obstruction

Year:  2022        PMID: 35966377      PMCID: PMC9374527          DOI: 10.1055/s-0041-1740044

Source DB:  PubMed          Journal:  Clin Colon Rectal Surg        ISSN: 1530-9681


  47 in total

Review 1.  Pseudo-obstruction in the critically ill.

Authors:  Silvia Delgado-Aros; Michael Camilleri
Journal:  Best Pract Res Clin Gastroenterol       Date:  2003-06       Impact factor: 3.043

2.  The successful treatment of acute refractory pseudo-obstruction with prucalopride.

Authors:  C J Smart; A N Ramesh
Journal:  Colorectal Dis       Date:  2012-08       Impact factor: 3.788

3.  Acute Colonic Pseudo-obstruction: Defining the Epidemiology, Treatment, and Adverse Outcomes of Ogilvie's Syndrome.

Authors:  Samuel W Ross; Bindhu Oommen; Blair A Wormer; Amanda L Walters; Vedra A Augenstein; B Todd Heniford; Ronald F Sing; A Britton Christmas
Journal:  Am Surg       Date:  2016-02       Impact factor: 0.688

4.  Ogilvie's syndrome of false colonic obstruction; a case with post-mortem findings.

Authors:  J A DUNLOP
Journal:  Br Med J       Date:  1949-05-21

Review 5.  The enteric nervous system.

Authors:  R K Goyal; I Hirano
Journal:  N Engl J Med       Date:  1996-04-25       Impact factor: 91.245

6.  Neostigmine treatment protocols applied in acute colonic pseudo-obstruction disease: A retrospective comparative study.

Authors:  Ömür İlban; Faruk Çiçekçi; Jale Bengi Çelik; Mehmet Ali Baş; Ateş Duman
Journal:  Turk J Gastroenterol       Date:  2019-03       Impact factor: 1.852

7.  Subcutaneous neostigmine appears safe and effective for acute colonic pseudo-obstruction (Ogilvie's syndrome).

Authors:  Adam Frankel; Christopher Gillespie; Cu-Tai Lu; Peter Hewett; David Wattchow
Journal:  ANZ J Surg       Date:  2019-05-13       Impact factor: 1.872

8.  Pseudo-obstruction associated with colonic ischemia: successful management with colonoscopic decompression.

Authors:  J J Fiorito; R E Schoen; L J Brandt
Journal:  Am J Gastroenterol       Date:  1991-10       Impact factor: 10.864

9.  Acute pseudo-obstruction of the colon (Ogilvie's syndrome). An analysis of 400 cases.

Authors:  V W Vanek; M Al-Salti
Journal:  Dis Colon Rectum       Date:  1986-03       Impact factor: 4.585

10.  Safety and efficacy of percutaneous cecostomy/colostomy for treatment of large bowel obstruction in adults with cancer.

Authors:  Sanjit O Tewari; George I Getrajdman; Elena N Petre; Constantinos T Sofocleous; Robert H Siegelbaum; Joseph P Erinjeri; Martin R Weiser; Raymond H Thornton
Journal:  J Vasc Interv Radiol       Date:  2014-12-17       Impact factor: 3.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.